title: Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
abstract: Primary myelofibrosis (PMF) is characterized by fibrosis, ineffective hematopoiesis in marrow, and hematopoiesis in extramedullary sites and is associated with abnormal megakaryocyte (MK) development and increased transforming growth factor (TGF)-β1 release. To clarify the role of TGF-β1 in the pathogenesis of this disease, the TGF-β1 signaling pathway of marrow and spleen of the Gata1(low) mouse model of myelofibrosis (MF) was profiled and the consequences of inhibition of TGF-β1 signaling on disease manifestations determined. The expression of 20 genes in marrow and 36 genes in spleen of Gata1(low) mice was altered. David-pathway analyses identified alterations of TGF-β1, Hedgehog, and p53 signaling in marrow and spleen and of mammalian target of rapamycin (mTOR) in spleen only and predicted that these alterations would induce consequences consistent with the Gata1(low) phenotype (increased apoptosis and G1 arrest both in marrow and spleen and increased osteoblast differentiation and reduced ubiquitin-mediated proteolysis in marrow only). Inhibition of TGF-β1 signaling normalized the expression of p53-related genes, restoring hematopoiesis and MK development and reducing fibrosis, neovascularization, and osteogenesis in marrow. It also normalized p53/mTOR/Hedgehog-related genes in spleen, reducing extramedullary hematopoiesis. These data identify altered expression signatures of TGF-β1 signaling that may be responsible for MF in Gata1(low) mice and may represent additional targets for therapeutic intervention in PMF.
authors: Department of Medicine, Campus Biomedico, Istituto Superiore di Sanitá, Rome, Italy.
authors: Maria
authors: M
authors: Zingariello
authors: Fabrizio
authors: F
authors: Martelli
authors: Fiorella
authors: F
authors: Ciaffoni
authors: Francesca
authors: F
authors: Masiello
authors: Barbara
authors: B
authors: Ghinassi
authors: Emanuela
authors: E
authors: D'Amore
authors: Margherita
authors: M
authors: Massa
authors: Giovanni
authors: G
authors: Barosi
authors: Laura
authors: L
authors: Sancillo
authors: Xiaochun
authors: X
authors: Li
authors: Judith D
authors: JD
authors: Goldberg
authors: Rosa Alba
authors: RA
authors: Rana
authors: Anna Rita
authors: AR
authors: Migliaccio
mesh_terms: D000328:Adult; D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D015153:Blotting, Western; D001853:Bone Marrow / Q000378:metabolism / Q000473:pathology; D016022:Case-Control Studies; D054377:Chemokine CXCL12 / Q000235:genetics / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005434:Flow Cytometry; D050982:GATA1 Transcription Factor / Q000502:physiology*; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D055728:Primary Myelofibrosis / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D054377:Chemokine CXCL12; C515256:Cxcl12 protein, mouse; D016207:Cytokines; D050982:GATA1 Transcription Factor; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D053773:Transforming Growth Factor beta1; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases